104 related articles for article (PubMed ID: 30135292)
41. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
42. Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis.
Guppy KH; Akins PT; Moes GS; Prados MD
J Neurosurg Spine; 2009 Jun; 10(6):557-63. PubMed ID: 19558288
[TBL] [Abstract][Full Text] [Related]
43. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract][Full Text] [Related]
44. Grade II oligodendroglioma localized to the corpus callosum.
Monaco EA; Armah HB; Nikiforova MN; Hamilton RL; Engh JA
Brain Tumor Pathol; 2011 Oct; 28(4):305-9. PubMed ID: 21833577
[TBL] [Abstract][Full Text] [Related]
45. Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status.
Bourdillon P; Hlaihel C; Guyotat J; Guillotton L; Honnorat J; Ducray F; Cotton F
J Neurooncol; 2015 May; 122(3):529-37. PubMed ID: 25716744
[TBL] [Abstract][Full Text] [Related]
46. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
48. Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses.
Tanaka S; Hitotsumatsu T; Sugita Y; Ishido K; Ito O; Hatae R; Akagi Y; Yoshimoto K; Iihara K
Pathol Int; 2018 Oct; 68(10):567-573. PubMed ID: 30246385
[TBL] [Abstract][Full Text] [Related]
49. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ; Smits M; Kros JM; Chang SM
J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
[TBL] [Abstract][Full Text] [Related]
50. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
51. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G; Jenkins R
Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
[TBL] [Abstract][Full Text] [Related]
52. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
53. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
54. Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report.
Kocaeli H; Yakut T; Bekar A; Taşkapilioğlu O; Tolunay S
Surg Neurol; 2006 Dec; 66(6):627-30; discussion 630-1. PubMed ID: 17145331
[TBL] [Abstract][Full Text] [Related]
55. A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component.
Gadji M; Crous-Tsanaclis AM; Mathieu D; Mai S; Fortin D; Drouin R
Neuropathology; 2014 Apr; 34(2):170-8. PubMed ID: 24118308
[TBL] [Abstract][Full Text] [Related]
56. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
[TBL] [Abstract][Full Text] [Related]
57. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.
Chamberlain MC; Born D
J Neurooncol; 2015 Nov; 125(2):249-51. PubMed ID: 26341371
[TBL] [Abstract][Full Text] [Related]
59. Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report.
Uzuka T; Kakita A; Inenaga C; Takahashi H; Tanaka R; Takahashi H
Neurol Med Chir (Tokyo); 2007 Apr; 47(4):174-7. PubMed ID: 17457022
[TBL] [Abstract][Full Text] [Related]
60. Sarcoma-like tumor originating from oligodendroglioma.
Shoji T; Saito R; Kanamori M; Sonoda Y; Watanabe M; Tominaga T
Brain Tumor Pathol; 2016 Oct; 33(4):255-260. PubMed ID: 27333891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
